Generated Summary
This document is the first paper from the Review on Antimicrobial Resistance, initiated by the UK Prime Minister, to address the growing threat of drug-resistant infections. The Review aims to explore five key themes: the economic impact of antimicrobial resistance (AMR), strategies to reduce the rise of resistance, boosting the development of new antimicrobial drugs, exploring alternative therapies, and the need for international action. The research, based on scenarios, assesses the potential health and macroeconomic consequences globally, especially in emerging economies, if AMR is not tackled. The methodology employed includes high-level scenarios by RAND Europe and KPMG to assess the future impact of AMR, with each team using its methodology to estimate the effects on the world population and economic output. The study recognizes the limitations in the data available, particularly regarding bacterial infections, which likely leads to an underestimation of the true costs associated with AMR. The study estimates the severe impacts of drug resistance in 2050 and underscores the urgent need for improved surveillance of infections and collaborative, innovative research.
Key Findings & Statistics
- Antimicrobial-resistant infections currently claim at least 50,000 lives each year across Europe and the US alone.
- In 15 European countries more than 10% of bloodstream Staphylococcus aureus infections are caused by methicillin-resistant strains (MRSA), with several of these countries seeing resistance rates closer to 50%.
- Global consumption of antibiotics in human medicine rose by nearly 40% between 2000 and 2010.
- The BRIC countries plus South Africa accounted for three-quarters of this growth.
- Annual per-person consumption of antibiotics varies by more than a factor of 10 across all middle and high-income countries.
- There were an estimated 480,000 new cases of drug-resistant TB in 2013.
- The variation in the AMR problems of individual countries is linked to huge differences in how heavily they use antimicrobial drugs.
- The continued rise in resistance by 2050 would lead to 10 million people dying every year.
- A reduction of 2% to 3.5% in Gross Domestic Product (GDP) is projected.
- The world could lose up to 100 trillion USD due to the economic cost of antimicrobial drug resistance by 2050.
- 300 million people are expected to die prematurely because of drug resistance over the next 35 years.
- The world’s GDP will be 2 to 3.5% lower than it otherwise would be in 2050.
- The world can expect to lose between 60 and 100 trillion USD worth of economic output if antimicrobial drug resistance is not tackled between now and 2050.
- The world’s GDP will be 0.5% smaller by 2020.
- The world’s GDP will be 1.4% smaller by 2030.
- Over 100 million people will have died prematurely by 2030.
- Caesarean sections contribute about 2% to world GDP.
- Joint replacements add about 0.65% to world GDP.
- Cancer drugs add more than 0.75% to world GDP.
- Organ transplants add about 0.1% to world GDP.
- These interventions aggregate to almost 4% of the world’s GDP.
- The economic loss from the above is worth at least 120 trillion USD between now and 2050.
- The world’s economy could lose more than 7% of its GDP by 2050, or a total of 210 trillion USD over the next 35 years.
- The cumulative loss of economic output by 2050 for countries in the OECD will amount to between USD 20 and 35 trillion.
Other Important Findings
- AMR threatens many of the most important medical advances that have been made.
- The problem is not just confined to bacteria, but all microbes that have the potential to mutate and render drugs ineffective.
- AMR has a significant impact on the safety of childbirth, including cesarean sections.
- The variation in the AMR problems of individual countries is linked to huge differences in how heavily they use antimicrobial drugs.
- Any use of antimicrobials, however appropriate and conservative, contributes to the development of resistance, but widespread unnecessary and excessive use makes it worse.
- The development of resistance is an evolutionary inevitability, even where antimicrobials are used properly and sparingly.
- Drug-resistant malaria could constrain the economic progress achieved by some countries in Asia.
- The study showed a loss of output that will be producing between 2% and 3.5% less than it otherwise would.
- The secondary health effects of AMR could have serious and negative impacts on middle income countries that are expected to build universal health systems over the coming decades.
- The reaction is likely to be a growing aversion to travel in a world with dramatic and widespread AMR problems.
Limitations Noted in the Document
- The studies looked only at a subset of drug-resistant bacteria and public health issues due to the lack of readily available data.
- The research was commissioned to understand the economic cost of AMR, interpreted strictly as its impact on global GDP, other issues such as social and healthcare costs, were not considered.
- The studies were hampered by a lack of reliable data, particularly regarding bacterial infections, and as a consequence, they most likely underestimate the true cost of AMR.
- RAND Europe and KPMG used current regional data to try and estimate how anti-malarial resistance is likely to rise, which was considered as proxies in the absence of better data or forecasting tools.
- Both teams experienced significant problems with data collection because of the lack of consistent sources monitoring the number of bacterial infections globally, these problems were severe in OECD as well as non-OECD countries.
Conclusion
The Review on Antimicrobial Resistance underscores the critical need to address the global crisis of drug-resistant infections. The research highlights the potential for devastating consequences, including millions of deaths annually and trillions of dollars in economic losses if action is not taken. The study reveals that AMR is not only a major health concern but also poses significant economic risks, particularly for emerging economies and those already grappling with high rates of diseases like malaria, HIV, and TB. The analysis emphasizes the importance of a multi-pronged approach, encompassing not only treating infections but also reducing and controlling their spread. Furthermore, the research underscores the need for international collaboration, accelerated research, and investment in healthcare infrastructure and sanitation to combat AMR effectively. The document emphasizes that acting quickly is crucial and that delaying action could lead to substantial losses. The Review calls for concerted efforts from policymakers, researchers, industry, and philanthropic organizations to tackle the rise of antimicrobial drug resistance. It also highlights the alignment of tackling drug resistance with the growth objectives of low and middle-income economies. The document concludes with a sense of optimism, emphasizing that the crisis is solvable if the right steps are taken collectively. The insights presented in the Review advocate for a unified and proactive response to mitigate the impact of AMR and preserve the advances in medicine and public health that have been made over the past decades.